Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
ETEton Pharmaceuticals, Inc. logo

Eton Pharmaceuticals, Inc. (ETON)

NASDAQ · Currency in USD
$50.00 ▼ -0.02 (-0.04%)
At close: Oct 23, 4:00 PM ET. Market closed.
$50.98 ▲ +0.98 (+1.96%)
After hours: Oct 23, 7:57 PM ET

Summary

Previous Close
$50.02
Open
$49.89
Day's Range
$48.75 – $50.74
52 Week Range
$14.27 – $66.37
Volume
308,086
Avg. Volume
562,768
Market Cap
$1.43B
Beta (5Y Monthly)
0.90
PE Ratio (TTM)
107.53
EPS (TTM)
$0.46
Earnings Date
Nov 5, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$72.00

Profile: Eton Pharmaceuticals, Inc.

Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Full-time employees
44
CEO
Sean E. Brynjelsen

Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis.

Earnings

Next report: Thu, Nov 5, 2026
EPS estimate $0.31 · Revenue est. $41.98M
DateEst.Actual
Aug 13, 2026$0.19$0.35Beat
May 14, 2026$0.10$0.05Miss
Mar 19, 2026$0.12$0.05Miss
Nov 6, 2025$0.16-$0.07Miss
Aug 7, 2025-$0.01-$0.10Miss
May 13, 2025$0.09$0.07Miss

Analyst view

Consensus price target
$72.00 ▲ +44.0%
Range $68.00 – $78.00
Rating: Buy
Buy 100% · Hold 0% · Sell 0%

Get free alerts on ETON and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.